Product Description
Brequinar is a synthetic quinolinecarboxylic acid analogue with antineoplastic properties. Brequinar inhibits the enzyme dihydroorotatedehydrogenase, thereby blocking de novo pyrimidine biosynthesis. This agent may also enhance the in vivo antitumor effect of antineoplastic agents such as 5-FU. (Sourced from: https://pubchem.ncbi.nlm.nih.gov/compound/Brequinar)
Mechanisms of Action: DHODH Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Clear Creek Bio
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: COVID-19|Acute Myeloid Leukemia
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| CCBCRISIS04 | P2 |
Terminated |
COVID-19 |
2022-06-04 |
66% |
2023-02-07 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments |
| CRISIS2 | P2 |
Completed |
COVID-19 |
2021-04-28 |
28% |
2021-07-28 |
Primary Endpoints|Treatments|Trial Status |
| CCB-01 | P2 |
Terminated |
Acute Myeloid Leukemia |
2020-12-31 |
16% |
2022-08-09 |
Primary Endpoints |
| CRISIS | P2 |
Completed |
COVID-19 |
2020-12-29 |
48% |
2022-02-17 |
Patient Enrollment|Primary Endpoints|Start Date|Study Completion Date|Treatments |